Sickle Cell Anemia Therapeutics Market :
A drastic reduction in the total red blood cells or RBC count or hemoglobin is known as anemia. It can be defined as the inability to carry optimum amount of oxygen by the blood. Sickle-cell diseases (SCD) are types of blood disorders which are usually inherited genetically. One of the common types of SCDs is the sickle-cell anemia or SCA. It essentially gives rise to an irregularity in hemoglobin, the protein that carries oxygen in the blood. Hemoglobin is found typically in the red blood cells of the body. As a result a sickle-like shaped cell is formed under certain conditions. Tribulations in sickle cell disease usually start to take shape at a very early age (within the first year of birth). This might lead to various health problems including pain attacks also known as the sickle-cell crisis, swelling in the limbs, microbial infections, and in certain cases, stroke. Chronic pain may develop with age. Sickle-cell diseases arise when an individual inherits abnormal copies of hemoglobin gene from each parent.
Sickle Cell Anemia Therapeutics Market
On the basis of type of medication, the global market is classified into:
Antibiotics
Pain-relieving medications
Hydroxyurea
Others
On the basis of end user, the global market is classified into:
Government
Hospitals
Private Clinics
Others

The National Center for Biotechnology Information says that sickle cell anemia is one of the most common hereditary hematological diseases among humans. Annually, around 250,000 children are born with the disease and it is among the most occurring epidemiological genetic diseases worldwide. Governments around the world, especially in Africa are taking initiatives to prevent and cure the disease as a result of which, huge investments on this field are expected in the coming years. This in turn will encourage the manufacturers around the world to manufacture in large quantities to meet the unmet demand thereby propelling the growth of the sickle cell anemia therapeutics market.

Increasing occurrence of the disease especially in the Africa region will drive the sickle cell anemia therapeutics market
According to the World Health Organization, around 5% of the population around the globe carries the gene for the sickle cell disease. This percentage is as high as 25% in some of the regions around the world. According to the same report, WHO has estimated that the occurrence of sickle cell disease is highest in the African region. To meet this crisis of high prevalence of the disease, WHO’s governing bodies has taken initiatives to address the same. Moreover, according to PLOS Medicine, the occurrence of sickle cell anemia is likely to rise by around 30% by 2050, especially in the sub-Saharan Africa. This rise in demand will eventually push the global sickle cell anemia therapeutics market into a positive growth trajectory over the course of the forecast period (2016-2024).

Manufacturers around the world are competing on the availability of technologically advanced drugs for the treatment of sickle cell anemia. Key players operating in the global sickle cell anemia therapeutics market are Bristol-Myers Squibb, GlycoMimetics, Pfizer,Anthera Pharmaceuticals Inc., GlycoMimetics, Inc., Eli Lilly, and Mast Therapeutics.Some of the other manufacturers are Daiichi Sankyo, Novartis Pharmaceuticals, Bluebird Bio, HemaQuest Pharmaceuticals Inc., Emmaus Medical, HemaQuest Pharmaceuticals, Baxter, and Merck Sharp & Dohme.

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.